Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 145 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: CP Clear all

Conditions: Chronic Phase Chronic Myelogenous Leukemia
Interventions: Asciminib 40 MG, Asciminib 40 MG Twice Daily, Asciminib 80 MG daily, Imatinib, Nilotinib, Dasatinib; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 5
States / cities: Detroit, Michigan • Buffalo, New York • New York, New York + 2 more

Conditions: Myeloid Leukemia, Philadelphia Positive
Interventions: Asciminib Pediatric formulation group, Asciminib Adult formulation group; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 3
States / cities: Indianapolis, Indiana • Boston, Massachusetts • New York, New York

Conditions: Sarcoma, Ewing's
Interventions: CP-751,871; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 9 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Rochester, Minnesota

Conditions: Melanoma
Interventions: CP 870,893, Peptides, Oncovir poly IC:LC; Drug · Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Myelogenous Leukemia, Chronic
Interventions: nilotinib, imatinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 846 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2019
U.S. locations: 31
States / cities: Los Angeles, California • San Diego, California • Vallejo, California + 27 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: CP-751,871, paclitaxel, carboplatin, erlotinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 26
States / cities: Tucson, Arizona • Greenbrae, California • Los Angeles, California + 15 more

Conditions: Cerebral Palsy (CP), Intelligibility, Speech, Augmentative and Alternative Communication
Interventions: AAC Speech supplementation; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 7 Years to 17 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Chronic Myelogenous Leukemia
Interventions: Nilotinib followed by treatment-free; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2025
U.S. locations: 10
States / cities: Fort Myers, Florida • Miami Lakes, Florida • Tampa, Florida + 7 more

Conditions: Solid Tumors
Interventions: CP-870,893; Biological
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Severe Acute Respiratory Syndrome, COVID
Interventions: SARS-CoV-2 plasma; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Novi, Michigan • Southfield, Michigan • Warren, Michigan

Conditions: Upper Extremity Impairments, Cerebral Palsy (CP), ALS - Amyotrophic Lateral Sclerosis, Rett Syndrome
Interventions: One-week trial of Obi Medical device, which provides robotic assistance with feeding to persons with upper extremity impairments who are unable to self-feed in the traditional manner using utensils; Device
Lead sponsor: Desin LLC; Industry
Eligibility: 5 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Cerebral Palsy (CP)
Interventions: Pediatric Lower Limb Exoskeleton (Bambini Teens); Device
Lead sponsor: COSMO ROBOTICS CO., Ltd; Industry
Eligibility: 5 Years to 14 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Cerebral Palsy (CP), Dysarthria
Interventions: Speech only, Hand/Arm only, Speech and arm combined; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 8 Years to 17 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Aortic Coarctation
Interventions: Treatment of Aortic Wall Injury; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: Not listed
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 19
States / cities: San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 16 more

Conditions: Spastic/Dystonic Quadriplegia, Cerebral Palsy (CP)
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 6 Years to 25 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cerebral Palsy, Hemiplegia, Children, Pediatric
Interventions: Constraint-Induced Movement Therapy (CIMT), Hand-Arm Bimanual Intensive Therapy (HABIT); Procedure
Lead sponsor: Teachers College, Columbia University; Other
Eligibility: 30 Months to 14 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSV LID cp ΔM2-2 Vaccine, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 24 Months
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Baltimore, Maryland • Laurel, Maryland

Conditions: Healthy Children, CP (Cerebral Palsy), CP, Cerebral Palsy
Interventions: Brain-Computer Interface (BCI)-HABIT-VR, Hand and Bimanual Intensive Therapy Virtual Reality (HABIT-VR); Device
Lead sponsor: University of Nebraska; Other
Eligibility: 6 Years to 17 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Chronic Pain, Low Back Pain
Interventions: Computerized Chemosensory-Based Orbitofrontal Cortex Training for Pain, Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT); Combination Product
Lead sponsor: Evon Medics LLC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Pasadena, Maryland

Conditions: Cerebral Palsy, Spastic, Telemedicine
Interventions: Telehealth home exercise program; Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 11 Years to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Chronic Phase Chronic Myeloid Leukemia
Interventions: Dasatinib; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 5
States / cities: Anaheim, California • Southington, Connecticut • Baltimore, Maryland + 2 more

Conditions: Leukemia, Myeloid, Chronic Phase
Interventions: Imatinib mesylate; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 476 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 50
States / cities: Mobile, Alabama • Berkeley, California • Campbell, California + 35 more

Conditions: Cerebral Palsy (CP)
Interventions: Pathways and Resources for Engagement and Participation, Attention Control Condition; Behavioral
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 13 Years to 17 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Cerebral Palsy, CP, Spastic Cerebral Palsy
Interventions: Autologous UCB Reinfusion, Placebo; Biological · Other
Lead sponsor: Joanne Kurtzberg, MD; Other
Eligibility: 12 Months to 6 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors

Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100

A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer

Speech Production Enhancement Using Augmentative Communication for Kids

Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients

Redosing With CP-870, 893 in Patients With Clinical Benefit After a Single Infusion From A Phase I, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors

Intermediate IND Severe Illness COVID-19 CP

Obi Medical Robot: Evaluating Effectiveness Related to Usability

Evaluating the Bambini Teens Exoskeleton for Pediatric Cerebral Palsy

Speech and Arm Combined Exergame

Covered CP Stents for the Prevention or Treatment of Aortic Wall Injury Associated With Coarctation of the Aorta

Outcomes of Neurosurgical Tone Management

Constraint-induced Movement Therapy (CIMT) and Bimanual Training (HABIT) in Children With Hemiplegic Cerebral Palsy

Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants and Children 6 to 24 Months of Age

Training Upper Limbs of Neurodiverse Children by Connecting Brain Activities to a Virtual Reality Based Game

Development and Evaluation of Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment of Pain (CBOT-P)

The Feasibility of Telehealth HEP for CP (HEP: Home Exercise Program), (CP: Cerebral Palsy)

Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib

Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity)

Metacognitive Strategy Training Intervention for Transition-Age Youth With Cerebral Palsy

A Randomized Study of Autologous Umbilical Cord Blood Reinfusion in Children With Cerebral Palsy